Home
HelixAI
Features
Use cases
Knowledge bases
Stakeholder mapping
Clinical and scientific landscaping
Competitive landscaping
Self-serve analytics
Easily explore data visualizations and structured insights across multiple sources.
Read more
Integrated insights feed
Collaborate in real time by commenting, discussing, and refining intelligence directly within the platform.
Read more
Custom alerts
Set personalized alerts for new intelligence that impacts your strategy.
Read more
AI-enhancements
AI-powered summarization and conversational AI distill dense publications into clear takeaways.
Read more
HelixAI
Analyze your landscape in seconds with an AI-enhanced knowledge management platform built around your unique situation.
Explore HelixAI
Watch demo
Medical Affairs
Stay ahead of the scientific conversation and build stronger engagement strategies.
Read more
Market Access
Deliver confident, evidence-backed decisions in dynamic and budget-constrained environments.
Read more
Clinical Development
Compare competitor activity, synthesize key publications, and identify the smartest sites and endpoints.
Read more
Cross-functional teams
Every insight is linked, every decision is grounded, and every update builds on what’s already known.
Read more
HelixAI use cases
Analyze your landscape in seconds with an AI-enhanced knowledge management platform built around your unique situation.
Use cases
Watch demo
Stakeholder mapping
Key Opinion Leaders (KOLs)
Optimize your stakeholder engagement strategy.
Digital Opinion Leaders (DOLs)
Learn how DOLs are emerging as powerful voices.
Rising Stars
Discover the KOLs of tomorrow, today.
Research center analysis
New
Enhance your stakeholder engagement strategy.
.
Payer Influencing Key Opinion Leaders (PIKOLs)
Increase your likelihood of launch success with PIKOLs.
Key Clinical Investigators (KCIs)
Elevate your clinical trial strategy through KCIs.
Trial site analysis
Adopt a data-driven approach to site selection.
Clinical landscaping
Epidemiology
Lead a more targeted approach.
Burden of disease and unmet needs
Drive informed decision-making.
Scientific landscaping
Bibliometric analysis
Reveal emerging research, trends, and collaborators.
Journal scoping
Maximize the impact of your publication strategy.
Digital listening
New
Surface invaluable insights from the online conversation.
Competitive landscaping
Development pipelines
Inform drug and trial design, and comparative effectiveness.
Marketed products, regulatory approvals, and HTA decisions
Understand regulatory approval processes.
Market value and price benchmarking
Minimize risk and promote informed decision-making.
Consulting
Collaborative consulting
Asset evaluation
Attractiveness, market viability, and likelihood for success.
Conference listening
Surface valuable insights from online conversations surrounding a key event.
Digital effectiveness
Influencer mapping, message resonance, real-time scientific communication optimization.
Launch sequence optimization
Determine tactical market launch strategies.
Strategic pricing and reimbursement
Elevate strategic pricing and reimbursement decision-making.
.
Clinical development optimization
Inform clinical development decisions, design robust clinical trials.
Conference planning
Maximize meaningful participation at conferences.
Indication assessment
Establish the potential market opportunity within product development.
Product value communication
Craft a compelling value proposition to more effectively communicate.
Target product profile (TPP) design
Clinically aligned, commercially viable, strategically differentiated TPP design.
Related case studies
Understanding market opportunities to create compelling product value communications
Understanding market opportunity to effectively communicate its early value proposition to various stakeholders.
Read more
Strategic design of a Phase 3 clinical trial to maximize the likelihood of treatment approval
Maximizing the likelihood of your candidate becoming a standard-of-care therapy.
Read more
Read all case studies
Discover consulting
Get in touch
HelixAI
Consulting
About
Resources
Glossary
Resources
Resources
Case studies
Learn how we have helped our clients to make impactful changes.
Our stories
Read about the day-to-day lives of VISFO's team members.
Press releases
Hot off the press! Our latest news features and events.
.
Insights
Explore the latest insights and knowledge from the field.
Partnerships
Updated
See who we have joined together with to deliver excellence.
Glossary
Resource of commonly used terms within the sector.
Featured insights
Why better asset evaluation needs to begin earlier than you think
Read more
What we mean by compliant AI (and why it matters for pharma teams)
Read more
Read all insights
Resources area
Get in touch
Contact
VISFO
Glossary
Glossary of terms
Resource of commonly used terms within the sector.
AI-enhanced knowledge base
An AI-enhanced knowledge base integrates machine learning and natural language processing to organize, interpret, and surface relevant insights from vast scientific datasets.
AI-enhanced knowledge base
An AI-enhanced knowledge base integrates machine learning and natural language processing to organize, interpret, and surface relevant insights from vast scientific datasets.
Accelerated approval
Accelerated approval is a regulatory pathway that allows earlier market access for therapies that address serious conditions and fill an unmet medical need based on surrogate endpoints.
Accelerated approval
Accelerated approval is a regulatory pathway that allows earlier market access for therapies that address serious conditions and fill an unmet medical need based on surrogate endpoints.
Addressable population
The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.
Addressable population
The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.
Advisory board
An advisory board is a structured meeting where external experts provide insights to support strategic, clinical, or scientific decision-making in pharmaceutical development.
Advisory board
An advisory board is a structured meeting where external experts provide insights to support strategic, clinical, or scientific decision-making in pharmaceutical development.
Artificial intelligence
Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.
Artificial intelligence
Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.
Asset evaluation
An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.
Asset evaluation
An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.
Attribution
Attribution refers to the process of linking a scientific, clinical, or strategic outcome to a specific source, action, or stakeholder, ensuring transparency and traceability.
Attribution
Attribution refers to the process of linking a scientific, clinical, or strategic outcome to a specific source, action, or stakeholder, ensuring transparency and traceability.
Benefit-risk assessment
Benefit-risk assessment is the structured evaluation of a treatment’s positive therapeutic effects against its potential risks, informing regulatory and clinical decisions.
Benefit-risk assessment
Benefit-risk assessment is the structured evaluation of a treatment’s positive therapeutic effects against its potential risks, informing regulatory and clinical decisions.
Bibliometric analysis
Bibliometric analysis is the application of statistical methods to the study of publication data.
Bibliometric analysis
Bibliometric analysis is the application of statistical methods to the study of publication data.
Bibliometrics
Bibliometrics refers to the quantitative analysis of academic publications used to evaluate research performance and influence.
Bibliometrics
Bibliometrics refers to the quantitative analysis of academic publications used to evaluate research performance and influence.
Biosimilar
A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.
Biosimilar
A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.
Burden of proof
In market access and regulatory contexts, burden of proof refers to the obligation of pharmaceutical companies to demonstrate the value, efficacy, and safety of their products to key stakeholders.
Burden of proof
In market access and regulatory contexts, burden of proof refers to the obligation of pharmaceutical companies to demonstrate the value, efficacy, and safety of their products to key stakeholders.
Channel strategy
Channel strategy refers to how pharmaceutical companies engage different communication and access pathways to reach key stakeholders across medical, payer, and patient channels.
Channel strategy
Channel strategy refers to how pharmaceutical companies engage different communication and access pathways to reach key stakeholders across medical, payer, and patient channels.
Clinical benefit
Clinical benefit refers to the positive impact a treatment has on patient health, including symptom relief, disease modification, or survival improvement.
Clinical benefit
Clinical benefit refers to the positive impact a treatment has on patient health, including symptom relief, disease modification, or survival improvement.
Clinical development
Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.
Clinical development
Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.
Clinical differentiation
Clinical differentiation is the degree to which a product stands out from alternatives based on its therapeutic profile, safety, or ease of use.
Clinical differentiation
Clinical differentiation is the degree to which a product stands out from alternatives based on its therapeutic profile, safety, or ease of use.
Clinical landscape
The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.
Clinical landscape
The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.
Clinical landscaping
Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.
Clinical landscaping
Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.
Clinical meaningfulness
Clinical meaningfulness describes the real-world relevance of a treatment’s effects on outcomes that matter to patients, providers, and payers.
Clinical meaningfulness
Clinical meaningfulness describes the real-world relevance of a treatment’s effects on outcomes that matter to patients, providers, and payers.
Co-author impact factor
Co-author impact factor is a derived metric that assesses the influence of an author’s collaborators based on their publication activity and citation history.
Co-author impact factor
Co-author impact factor is a derived metric that assesses the influence of an author’s collaborators based on their publication activity and citation history.
Collaboration network
A collaboration network is a visual or analytical representation of co-authorship and institutional relationships within scientific research communities.
Collaboration network
A collaboration network is a visual or analytical representation of co-authorship and institutional relationships within scientific research communities.
Comparative effectiveness
Comparative effectiveness evaluates how a treatment performs relative to other available options in terms of efficacy, safety, and real-world outcomes.
Comparative effectiveness
Comparative effectiveness evaluates how a treatment performs relative to other available options in terms of efficacy, safety, and real-world outcomes.
Competitive landscape
The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.
Competitive landscape
The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.
Competitive landscaping
Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.
Competitive landscaping
Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.
Conference landscape
The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.
Conference landscape
The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.
Conference landscaping
Conference landscaping is the systematic analysis of relevant scientific and medical meetings to identify key themes, trends, stakeholders, and strategic opportunities.
Conference landscaping
Conference landscaping is the systematic analysis of relevant scientific and medical meetings to identify key themes, trends, stakeholders, and strategic opportunities.
Conference planning
Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.
Conference planning
Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.
DOL impact factor
At VISFO, a Digital Opinion Leader (DOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank DOLs.
DOL impact factor
At VISFO, a Digital Opinion Leader (DOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank DOLs.
Decentralized clinical trial (DCT)
A decentralized clinical trial (DCT) is a study that uses digital tools and remote methods to reduce or eliminate the need for in-person site visits.
Decentralized clinical trial (DCT)
A decentralized clinical trial (DCT) is a study that uses digital tools and remote methods to reduce or eliminate the need for in-person site visits.
Development pipeline
A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.
Development pipeline
A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.
Digital Opinion Leader (DOL)
A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.
Digital Opinion Leader (DOL)
A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.
Digital activity
Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.
Digital activity
Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.
Digital landscape
The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.
Digital landscape
The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.
Digital landscaping
Digital landscaping is the structured analysis of online activity to identify key stakeholders, emerging trends, and scientific conversations within a therapeutic area.
Digital landscaping
Digital landscaping is the structured analysis of online activity to identify key stakeholders, emerging trends, and scientific conversations within a therapeutic area.
Digital listening
Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.
Digital listening
Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.
Digital transformation
Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.
Digital transformation
Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.
Disease burden
Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.
Disease burden
Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.
Disease severity
Disease severity refers to the extent or intensity of a condition’s impact on a patient’s health, functioning, and quality of life.
Disease severity
Disease severity refers to the extent or intensity of a condition’s impact on a patient’s health, functioning, and quality of life.
Dose optimization
Dose optimization is the process of identifying the most effective and safe drug dose for a specific patient population.
Dose optimization
Dose optimization is the process of identifying the most effective and safe drug dose for a specific patient population.
Early access program (EAP)
An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.
Early access program (EAP)
An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.
Economic modeling
Economic modeling involves the use of mathematical frameworks to estimate the cost-effectiveness, budget impact, or value of healthcare interventions.
Economic modeling
Economic modeling involves the use of mathematical frameworks to estimate the cost-effectiveness, budget impact, or value of healthcare interventions.
Eligibility criteria
Eligibility criteria are the inclusion and exclusion rules that define which participants can enroll in a clinical trial.
Eligibility criteria
Eligibility criteria are the inclusion and exclusion rules that define which participants can enroll in a clinical trial.
Engagement planning
Engagement planning is the strategic design of how and when to interact with external stakeholders to support scientific, clinical, and commercial goals.
Engagement planning
Engagement planning is the strategic design of how and when to interact with external stakeholders to support scientific, clinical, and commercial goals.
Epidemiology
Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.
Epidemiology
Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.
Evidence hierarchy
An evidence hierarchy is a ranked framework that classifies types of evidence based on their methodological rigor and reliability.
Evidence hierarchy
An evidence hierarchy is a ranked framework that classifies types of evidence based on their methodological rigor and reliability.
Evidence-generation program
An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.
Evidence-generation program
An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.
External control arm
An external control arm uses data from outside a clinical trial to serve as a comparator for evaluating a treatment’s effectiveness.
External control arm
An external control arm uses data from outside a clinical trial to serve as a comparator for evaluating a treatment’s effectiveness.
Feasibility planning
Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.
Feasibility planning
Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.
First-author
First-author refers to the individual credited with leading the design, execution, and authorship of a scientific publication.
First-author
First-author refers to the individual credited with leading the design, execution, and authorship of a scientific publication.
Formulary inclusion
Formulary inclusion is the decision by a healthcare payer or institution to list a pharmaceutical product as an approved treatment option.
Formulary inclusion
Formulary inclusion is the decision by a healthcare payer or institution to list a pharmaceutical product as an approved treatment option.
Gap analysis
Gap analysis is the process of identifying missing evidence, insights, or capabilities needed to meet strategic, regulatory, or stakeholder expectations.
Gap analysis
Gap analysis is the process of identifying missing evidence, insights, or capabilities needed to meet strategic, regulatory, or stakeholder expectations.
Generic
A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.
Generic
A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.
Global value dossier (GVD)
A global value dossier (GVD) is a comprehensive document that compiles all supporting evidence for a product’s value, designed for use in payer and HTA submissions worldwide.
Global value dossier (GVD)
A global value dossier (GVD) is a comprehensive document that compiles all supporting evidence for a product’s value, designed for use in payer and HTA submissions worldwide.
HEOR stakeholder
An HEOR stakeholder is an individual or organization that uses health economics and outcomes research to guide decisions in healthcare policy, reimbursement, or treatment adoption.
HEOR stakeholder
An HEOR stakeholder is an individual or organization that uses health economics and outcomes research to guide decisions in healthcare policy, reimbursement, or treatment adoption.
HTA submission
An HTA submission is a formal package of clinical and economic evidence provided to a health technology assessment body to support product reimbursement or funding.
HTA submission
An HTA submission is a formal package of clinical and economic evidence provided to a health technology assessment body to support product reimbursement or funding.
Health Economics and Outcomes Research (HEOR)
HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.
Health Economics and Outcomes Research (HEOR)
HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.
Health economic model
A health economic model is a structured tool used to estimate the costs and outcomes associated with a healthcare intervention over time.
Health economic model
A health economic model is a structured tool used to estimate the costs and outcomes associated with a healthcare intervention over time.
Health technology assessment (HTA)
A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.
Health technology assessment (HTA)
A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.
Implementation science
Implementation science is the study of how to promote the adoption and integration of evidence-based practices into real-world healthcare settings.
Implementation science
Implementation science is the study of how to promote the adoption and integration of evidence-based practices into real-world healthcare settings.
Incidence
In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.
Incidence
In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.
Inclusion/exclusion criteria
Inclusion and exclusion criteria define who can or cannot participate in a clinical trial, based on factors like disease state, age, comorbidities, or prior treatment.
Inclusion/exclusion criteria
Inclusion and exclusion criteria define who can or cannot participate in a clinical trial, based on factors like disease state, age, comorbidities, or prior treatment.
Indication
Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.
Indication
Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.
Indication assessment
An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.
Indication assessment
An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.
Insight
An insight is understanding derived from data or a lived experience that reveals a trend, need, or opportunity.
Insight
An insight is understanding derived from data or a lived experience that reveals a trend, need, or opportunity.
Institutional affiliation
Institutional affiliation refers to the academic, research, or clinical organization with which a healthcare professional is formally associated.
Institutional affiliation
Institutional affiliation refers to the academic, research, or clinical organization with which a healthcare professional is formally associated.
Integrated evidence plan (IEP)
An integrated evidence plan (IEP) outlines the coordinated generation of clinical, economic, and real-world data to support a product’s lifecycle strategy.
Integrated evidence plan (IEP)
An integrated evidence plan (IEP) outlines the coordinated generation of clinical, economic, and real-world data to support a product’s lifecycle strategy.
Intelligence board
An intelligence board is an expert-curated synthesis of evidence, data, and strategic insights designed to support pharmaceutical decision-making on specific questions or topics.
Intelligence board
An intelligence board is an expert-curated synthesis of evidence, data, and strategic insights designed to support pharmaceutical decision-making on specific questions or topics.
Internal buy-in
Internal buy-in refers to gaining cross-functional agreement and support for a strategic decision, investment, or action plan within a pharmaceutical organization.
Internal buy-in
Internal buy-in refers to gaining cross-functional agreement and support for a strategic decision, investment, or action plan within a pharmaceutical organization.
Investigator-initiated study (IIS)
An investigator-initiated study (IIS) is a clinical or scientific study developed and led by an independent researcher, often supported by pharmaceutical funding or materials.
Investigator-initiated study (IIS)
An investigator-initiated study (IIS) is a clinical or scientific study developed and led by an independent researcher, often supported by pharmaceutical funding or materials.
Journal prestige
Journal prestige refers to the perceived authority, influence, and visibility of a scientific journal within its field, beyond its impact factor alone.
Journal prestige
Journal prestige refers to the perceived authority, influence, and visibility of a scientific journal within its field, beyond its impact factor alone.
KCI impact factor
At VISFO, a Key Clinical Investigator (KCI) impact factor is a proprietary bibliometric-based calculation used to identify and rank KCIs.
KCI impact factor
At VISFO, a Key Clinical Investigator (KCI) impact factor is a proprietary bibliometric-based calculation used to identify and rank KCIs.
KOL impact factor
At VISFO, a Key Opinion Leader (KOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank KOLs.
KOL impact factor
At VISFO, a Key Opinion Leader (KOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank KOLs.
Key Clinical Investigator (KCI)
A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.
Key Clinical Investigator (KCI)
A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.
Key Opinion Leader (KOL)
A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.
Key Opinion Leader (KOL)
A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.
Key Opinion Leader (KOL) mapping
Key Opinion Leader (KOL) mapping is the process of identifying and analyzing key opinion leaders based on their influence, expertise, and relevance to a specific therapeutic area or strategy.
Key Opinion Leader (KOL) mapping
Key Opinion Leader (KOL) mapping is the process of identifying and analyzing key opinion leaders based on their influence, expertise, and relevance to a specific therapeutic area or strategy.
Launch sequence optimization
Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.
Launch sequence optimization
Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.
Lifecycle evidence generation
Lifecycle evidence generation is the strategic planning and execution of data generation activities throughout a product’s development, launch, and post-market phases.
Lifecycle evidence generation
Lifecycle evidence generation is the strategic planning and execution of data generation activities throughout a product’s development, launch, and post-market phases.
Line of therapy
Line of therapy refers to the sequence in which treatments are given to a patient, typically categorized as first-line, second-line, or third-line based on clinical guidelines or treatment history.
Line of therapy
Line of therapy refers to the sequence in which treatments are given to a patient, typically categorized as first-line, second-line, or third-line based on clinical guidelines or treatment history.
Literature library
A literature library is a curated collection of publications relevant to a specific individual, topic, or strategy, used to support insight generation and engagement planning.
Literature library
A literature library is a curated collection of publications relevant to a specific individual, topic, or strategy, used to support insight generation and engagement planning.
Market Access
Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.
Market Access
Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.
Market Access Key Opinion Leader (MAKOL)
A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.
Market Access Key Opinion Leader (MAKOL)
A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.
Market conditioning
Market conditioning is the strategic process of shaping stakeholder awareness, perceptions, and expectations ahead of product launch or clinical milestone.
Market conditioning
Market conditioning is the strategic process of shaping stakeholder awareness, perceptions, and expectations ahead of product launch or clinical milestone.
Market potential
Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.
Market potential
Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.
Market shaping
Market shaping is the deliberate effort to redefine or expand a therapeutic space by influencing standards of care, stakeholder behavior, or access pathways.
Market shaping
Market shaping is the deliberate effort to redefine or expand a therapeutic space by influencing standards of care, stakeholder behavior, or access pathways.
Market value
Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.
Market value
Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.
Medical Affairs
Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.
Medical Affairs
Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.
Medical Science Liaison (MSL)
A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.
Medical Science Liaison (MSL)
A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.
Medical insight capture
Medical insight capture is the process of collecting, analyzing, and synthesizing insights from healthcare professionals to inform strategy and decision-making.
Medical insight capture
Medical insight capture is the process of collecting, analyzing, and synthesizing insights from healthcare professionals to inform strategy and decision-making.
Medical strategy
Medical strategy is the plan that guides how scientific and clinical knowledge is generated, interpreted, and communicated throughout a product’s lifecycle.
Medical strategy
Medical strategy is the plan that guides how scientific and clinical knowledge is generated, interpreted, and communicated throughout a product’s lifecycle.
Mentions
Mentions are instances where a specific product, topic, company, or stakeholder is referenced in digital content such as social media posts, articles, webinars, or forums.
Mentions
Mentions are instances where a specific product, topic, company, or stakeholder is referenced in digital content such as social media posts, articles, webinars, or forums.
Modeling
Modeling is the process of using mathematical frameworks to simulate clinical, economic, or epidemiological scenarios to support pharmaceutical decision-making.
Modeling
Modeling is the process of using mathematical frameworks to simulate clinical, economic, or epidemiological scenarios to support pharmaceutical decision-making.
Morbidity rate
Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.
Morbidity rate
Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.
Mortality rate
Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.
Mortality rate
Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.
Multi-stakeholder engagement
Multi-stakeholder engagement refers to the coordinated interaction with diverse healthcare decision-makers, including providers, payers, regulators, and patient advocates.
Multi-stakeholder engagement
Multi-stakeholder engagement refers to the coordinated interaction with diverse healthcare decision-makers, including providers, payers, regulators, and patient advocates.
Multiplicity
Multiplicity refers to the increased risk of false-positive results when multiple statistical tests are performed in a clinical trial.
Multiplicity
Multiplicity refers to the increased risk of false-positive results when multiple statistical tests are performed in a clinical trial.
Net clinical benefit
Net clinical benefit refers to the overall advantage of a treatment when weighing its therapeutic effects against its risks in real-world patient care.
Net clinical benefit
Net clinical benefit refers to the overall advantage of a treatment when weighing its therapeutic effects against its risks in real-world patient care.
Observational study
An observational study is a non-interventional research design that evaluates outcomes in patients receiving routine medical care.
Observational study
An observational study is a non-interventional research design that evaluates outcomes in patients receiving routine medical care.
Outcomes-based agreement
An outcomes-based agreement links a drug’s reimbursement to the real-world results it delivers in a patient population.
Outcomes-based agreement
An outcomes-based agreement links a drug’s reimbursement to the real-world results it delivers in a patient population.
PIKOL impact factor
At VISFO, a Payer Influencing Key Opinion Leader (PIKOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank PIKOLs.
PIKOL impact factor
At VISFO, a Payer Influencing Key Opinion Leader (PIKOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank PIKOLs.
Patient advocacy group
A patient advocacy group is an organization that represents the interests of individuals affected by a particular disease or condition, often influencing research, policy, and access.
Patient advocacy group
A patient advocacy group is an organization that represents the interests of individuals affected by a particular disease or condition, often influencing research, policy, and access.
Next
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.